secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001683168-24-005600
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing
--------------------------------------------------------------------------

- Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.
- Royalty payments from Takeda sublicense of PolyXen platform were $0.7M, up 11.6% YoY.
- Cash balance $7.3M at quarter end; expected to fund operations into clinical development.
- Preclinical studies for DNase oncology platform ongoing; data expected before year end.
- Advancing towards Phase 1 clinical proof-of-concept in pancreatic carcinoma and solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/0001683168-24-005600-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316824005600/xenetic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-005600

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer